Incyte Corporation: Carcinoma, Transitional Cell trials

The registry lists 12 Carcinoma, Transitional Cell studies with Incyte Corporation as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 8Phase 2 7Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial CarcinomaTerminatedNCT04586244Phase 2Results posted
• Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)TerminatedNCT04003610Phase 2Results posted
• Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial CarcinomaCompletedNCT03374488Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid TumorsTerminatedNCT03361228Phase 1/2Results posted
• INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic MalignanciesTerminatedNCT03277352Phase 1/2Results posted
• A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03241173Phase 1/2Results posted
• Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03126110Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)CompletedNCT02872714Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsTerminatedNCT04272034Phase 1
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsCompletedNCT04242199Phase 1
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesCompletedNCT03652077Phase 1
• A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 1